

Falnidamol

Catalog No: tcsc0691



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

196612-93-8

Formula:

$C_{18}H_{19}ClFN_7$

Pathway:

JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

Target:

EGFR;EGFR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 41 mg/mL (105.71 mM)

Alternative Names:

BIBX 1382

Observed Molecular Weight:

387.84


Product Description

Falnidamol (BIBX 1382) is a potent, selective inhibitor of EGFR tyrosine kinase ($IC_{50} = 3 \text{ nM}$); displays > 1000-fold lower potency against ErbB2 ($IC_{50} = 3.4 \text{ }\mu\text{M}$) and a range of other related tyrosine kinases ($IC_{50} > 10 \text{ }\mu\text{M}$).

IC50 & Target: IC50: 3 nM (EGFR)^[1].

In Vitro: Falnidamol (BIBX 1382) and BIBU1361 are both potent and selective submicromolar inhibitors of the EGFR kinase activity. An IC_{50} value of 3 nM was determined for both compounds. The potency of these two compounds compares with the one obtained with Iressa, which is a leading EGFR inhibitor in the field. Inhibition of the closest family member, HER2, was 100- to 1000-fold less potent. Furthermore, Falnidamol (BIBX 1382) and BIBU1361 did not inhibit a number of other related tyrosine kinases^[1].

In Vivo: In nude mice, oral once daily dosing at 10 mg/kg with either Falnidamol (BIBX 1382) or BIBU1361 completely suppressed tumor growth of human A431 xenografts with respective T/C values of 15 and 6% after 2 weeks of treatment^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!